TOP 10 COMPANIES IN NEXT GENERATION SEQUENCING (NGS) INFORMATICS MARKET

The Next Generation Sequencing (NGS) Informatics Market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% during the forecast period, says Meticulous Research^{® .}  Due to the substantial increase in data volume generated by NGS, there is a growing need for bioinformatics and computational skills to effectively analyze, interpret, manage, and store this data. NGS informatics companies are addressing this demand by enhancing their computational capabilities through hardware and developing specialized software.

These tools support various stages of the NGS data analysis process, from raw data processing to variant interpretation. The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects.

Here are the top 10 companies operating in the NGS Informatics Market

Illumina, Inc. (U.S.)

Incorporated in 1998 and headquartered in California, U.S., Illumina is a provider of sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The Core Illumina segment offers NGS informatics solutions to simplify workflows and accelerate analysis.

Illumina provides solutions to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.

Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries operating in the NGS market are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).

Thermo Fisher Scientific Inc. (U.S.)

Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment offers NGS informatics products and services such as data analysis using Torrent Suite Software and Next-Generation Sequencing Bioinformatics Training.

Thermo Fisher has a geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and distribution network. As of December 2022, the company had a headcount of 130,000 employees, of which 67,000 were employed in the Americas, 21,000 in Asia-Pacific, and 42,000 in Europe and the Middle East & Africa. Some of its major subsidiaries are Molecular Probes, Inc. (U.S.), Thermo Electron North America LLC (U.S.), Thermo Foundation, Inc. (U.S.), European Laboratory Holdings Limited (U.K.), and Patheon France SAS (France).

QIAGEN N.V. (Netherlands)

 Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences.

Qiagen’s product offerings include diagnostics solutions, PCR products, genomic or NGS products, consumables, and instruments for sample technologies. Furthermore, the company offers more than 500 core products consisting of instruments, kits, bioinformatics solutions, and a wide range of NGS services, such as RNA sequencing services, DNA sequencing services, whole genome amplification services, and RNA isolation services. These NGS informatics offerings are offered under the Genomics/NGS products category.

The company has a global presence, marketing its products in over 130 countries. It operates facilities in multiple countries, including the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, and the U.K. Sales are managed through distributors, sales subsidiaries, and direct sales to customers. Subsidiaries primarily handle sales in the Americas, Europe, Asia, and Australia.

Some of the major subsidiaries of the company are Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy). As of December 2020, the company had employed over 902 personnel for R&D.

Hoffmann-La Roche Ltd (Switzerland)

Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable segments: Pharmaceuticals and Diagnostics. It operates in the NGS informatics market through its Diagnostics segment.

The Diagnostics segment is engaged in developing a wide range of diagnostic products and solutions such as in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation, and IT, and decision support solutions.

Roche has a geographical presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide.

Some of its subsidiaries are Roche Diagnostics (U.S.), Roche Diagnostics GmbH (Germany), Roche Diagnostics France SAS (France), Roche Diagnostics S.p.A. (Italy), Roche Diagnostics International AG (Switzerland), Roche Diagnostics Limited (U.K.), Roche Diagnostics (Shanghai) Ltd. (China), and Roche Diagnostics K.K (Japan).

Agilent Technologies, Inc. (U.S.)

Founded in 1999 and headquartered in California, U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets; Agilent CrossLab; and Diagnostics and Genomics. The Diagnostics and Genomics segment offers the NGS informatics products market.

Agilent has a presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa and customers in over 110 countries through its subsidiaries and a strong distribution network. The company has research & development and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, Washington, Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.

Some of the company’s subsidiaries are Agilent Technologies Canada Inc. (Canada), Agilent Technologies UK Limited (U.K.), Agilent Technologies Deutschland GmbH (Germany), Agilent Technologies Company Limited (China), Agilent Technologies Japan, Ltd (Japan), Agilent Technologies Brasil Ltda. (Brazil), and Agilent Technologies France SAS (France).

Meticulous Research in its latest publication on Next Generation Sequencing (NGS) Informatics Market has predicted the growth of 15.4% during the forecast year 2023-2030.

DNAnexus, Inc. (U.S.)

Founded in 2009 and headquartered in California, U.S. DNAnexus, Inc. is a company that provides scalable, secure, and intuitive biomedical data analysis, bioinformatics, and software for healthcare and life sciences applications. The company supports and manages more than 65 petabytes of complex multi-omic, genomic, and clinical datasets and provides informatics solutions for multi-omics data science exploration, discovery & analysis, next-generation sequencing data analysis, and customized private & collaborative portals.

The company offers solutions to various end users, including biobanks, academic research institutions, clinical diagnostic laboratories, pharmaceutical companies, and government organizations. Its products are utilized by scientists in approximately 48 countries to gain insights into precision medicine, drive scientific discovery, and enhance patient care. Furthermore, the company’s offerings cater to nearly 100 enterprise customers across North America, Asia-Pacific, Europe, South America, and Africa.

Partek Incorporated (U.S.)

Founded in 1993 and headquartered in Missouri, U.S., Partek Incorporated is a company that provides bioinformatics software, bioinformatics services, and customer consultation to its customers to make scientific breakthroughs in disease relationships, human genetics, drug discoveries, and disease treatments & diagnoses.

The company’s solutions are used in multiple applications such as single-cell gene expression, gene expression, variant detection, CNV analysis, metagenomics, methylation, ChIP-Seq, and non-coding RNA expression.

The company provides its products to some of the major vendors around 25 countries across the globe, including Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), 10X Genomics, Inc. (U.S.), DO BIO (U.K.), and NanoString Technologies, Inc. (U.S.).

Fabric Genomics, Inc. (U.S.)

Founded in 2009 and headquartered in California, U.S., Fabric Genomics is a company that provides institutions with clinical sequencing solutions, including Fabric Enterprise software platform assay validation & design support and clinical interpretation services needed for genetic testing. The company provides its offerings for multiple applications, including oncology, rare disease, neurological, cardiovascular, and women’s health.

The company uses SOP-based workflows and an AI approach for genome interpretation, enabling rapid generation of clinical reports of genomic tests for physicians. Some of the key NGS software and services users of the company are hospitals, academic centers, and clinical laboratories such as Intermountain Healthcare (U.S.), Rady Children’s Institute for Genomic Medicine (U.S.), and Laboratory Corporation of America Holdings (U.S.).

DNASTAR, Inc. (U.S.)

Founded in 1984 and headquartered in Wisconsin, U.S., DNASTAR, Inc. is a company that provides bioinformatics solutions. The company primarily offers two product lines: DNASTAR Lasergene, a sequencing analysis software for genomics, molecular biology research, and protein analysis, and Nova Applications, a software for accurate protein structure modeling and prediction.

The company’s Lasergene software supports geneticists, molecular biologists, and structural biologists. It offers various functionalities, including RNA, DNA, and protein sequence analysis, next-generation sequence assembly and analysis, Sanger sequencing, protein structure analysis, antibody modeling, protein structure prediction, and protein docking. Lasergene is known for its flexibility, affordability, and user-friendly interface.

Sapio Sciences, LLC (U.S.)

Founded in 2004 and headquartered in Maryland, U.S., Sapio Sciences, LLC provides laboratory management, electronic lab notebook, and knowledge management solutions for the life sciences industry. The company provides LIMS solutions for various applications in research, clinical management, next-generation sequencing (NGS), histopathology, bioanalytical, biostability, and bioprocessing.

The company has a presence through its subsidiaries, such as Sapio Sciences Consulting (U.S.), Sapio Sciences Florida (U.S.), and Sapio Sciences London (U.K.).

Authoritative Research on the Next Generation Sequencing (NGS) Informatics Market – Global Opportunity Analysis and Industry Forecast (2023-2030)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

• Recent financial performance
• Key products
• Significant company strategies
• Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.